Introduction
Tissue factor (TF) is a 47 kDa glycosylated transmembrane protein consisting of a large extracellular domain and a short cytoplasmic domain. TF acts as the initiator of the extrinsic coagulation cascade. The zymogen factor VII (FVII) is the natural ligand to TF and gets activated to FVIIa upon binding to TF. The TF-FVIIa complex further activates factor IX and factor X eventually leading to fibrin deposition, platelet aggregation and formation of a thrombus (1).
In addition to its role in the coagulation cascade, TF is associated with cancer, reviewed in (1-3). TF expression has been found in all solid tumors and its expression has been linked to mutation of the K-ras oncogene, loss of p53 and PTEN tumor suppressor genes and tumor hypoxia (4) (5) (6) (7) . TF is involved in angiogenesis, invasiveness, tumor growth and anti-apoptotic signaling primarily through phosphorylation of its cytoplasmic domain and activation of the protease-activated receptor-2 (PAR2) axis by the TF-FVIIa complex (1,3).
Pancreatic cancer accounts for about 3% of all newly diagnosed cancers but due to its high mortality, pancreatic cancer accounts for 6% of all cancer associated deaths in the developed world (8) . About 85-90% of pancreatic cancers are adenocarcinomas with a 5-year survival of less than 10% (9, 10) .
Activating mutations in K-ras is the most common oncogenic mutation in pancreatic adenocarcinoma and is found in greater than 90% of the patients (10) . TF expression in pancreatic adenocarcinoma has been reported in 53-by on October 21, 2017 . For personal use only. jnm.snmjournals.org Downloaded from 89% of the tumors and the expression level has been associated with advanced stage, increased micro vessel density, metastasis and poor survival (11) (12) (13) . 
Materials and Methods
All chemicals were obtained from Sigma Aldrich unless stated otherwise.
FVIIai was obtained from Novo Nordisk A/S. p-SCN-Bn-NOTA was purchased from Macrocyclics. 64 Cu was produced by The Hevesy Laboratory at DTU Nutech using the 64 Ni(p,n) 64 Cu reaction and obtained in a dried formulation.
Synthesis of NOTA-FVIIai
A 10 mM stock solution of NOTA-Bn-NCS in HEPES buffer (50 mM HEPES, 10 mM CaCl 2 , 150 mM NaCl, pH 8.7) was mixed, and the pH was adjusted to 8.7. p-SCN-Bn-NOTA stock solution (258 nmol, 25 µL) was added to FVIIai (1 mL, 51.2 nmol, adjusted to pH 8.7) and incubated for 20 h at 37°C. The reaction mixture was purified on a PD-10 desalting column (GE Healthcare) in 0.5 mL fractions in ammonium acetate buffer (0.1 M ammonium acetate, 10 mM CaCl 2 , 150 mM NaCl, pH 5.5). The product was analyzed by HPLC (Supplementary Materials and Methods). Two fractions containing the highest amount of NOTA-FVIIai were mixed and the concentration was determined from a standard curve. The resulting NOTA-FVIIai was aliquoted in 150 µg portions, and frozen at -80°C for later use. The amount of functional chelator bound to each protein was determined by cold Cu titration as previously by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from described (21) . The experiment was performed in triplicates and analyzed by Image J software.
Radiolabeling of NOTA-FVIIai

64
Cu was mixed with ultrapure water and left at room temperature for 30 minutes before use. 50-80 µL (339-579 MBq) was added to a thawed vial of NOTA-FVIIai, and incubated for 15 minutes at 25°C. The resulting 64 Cu-NOTA-FVIIai was purified by PD-10 in 0.5 mL fractions in gly-gly buffer (10 mM gly-gly, 150 mM NaCl and 10 mM CaCl 2 , pH 7.5). Two fractions, containing most of the radioactivity, was mixed and analyzed. The concentration and radiochemical purity of Furthermore the stability was assess in mouse serum as previously described penicillin-streptomycin (Invitrogen) at 37˚C and 5% CO 2 . Cells were tested negative for mycoplasma and a panel of murine pathogens. Cell surface expression of TF was measured by flow cytometry as previously described (19) . Orthotopic tumor models were established as previously described (23) .
In brief, NMRI mice were anesthetized with sevoflurane and an incision was made in the left flank region distal of the pancreas. The spleen and pancreas were partly externalized and 5x10 
Biodistribution
Conventional ex vivo biodistribution was performed in a sub-group of animals after each of the imaging time-points (n=4 / time-point). Mice were by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from euthanized and the tumors and organs were resected, weighted and the radioactivity was counted in a gamma counter.
Radiation dosimetry estimation
Data from the ex vivo biodistribution performed at 1, 4, 15 and 36 hours after injection of 64 Cu-NOTA-FVIIai was used to estimate the human dosimetry. Estimations were made for a male and female phantom using the OLINDA/EXM version 1 software (24) . A dynamic bladder model was applied with a biological half-life of 1.5 hours, an elimination fraction of 75% and void interval of 5 hours.
Immunohistochemistry
Staining was performed as previously described (Paper 1), in brief: Formalin fixed paraffin embedded tumors were sectioned at 4 µm, deparaffinized, rehydrated and microwaved in citrate buffer pH 6 for epitope retrieval.
Sections were blocked with 2% bovine serum albumin in PBS and primary antibody against human tissue factor CD142 (#4508, American Diagnostica Inc.) was added at 1:800 dilution for 1 hour at room temperature. Primary antibody was detected by the EnVision+ System-HRP Labeled Polymer and Liquid DAB+ Substrate Chromogen System (Dako) before counterstaining with Mayer's Hematoxylin (Region H Apotek).
Statistical analysis
Unless stated otherwise, data are expressed as mean ± SEM. The effect of competition on the biodistribution data was evaluated by Multiple t-tests with by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from correction for multiple comparisons (Holm-Sidak). One-way ANOVA with post hoc test corrected for multiple comparisons (Turkey) was applied to test the biodistribution organ ratios and the uptake values in the different pancreatic cancer models. P values ≤ 0.05 were considered statistical significant.
Statistical analyses were performed using GraphPad Prism 6.0d.
Results
Radiochemistry
Functional chelator to protein amount was measured to 3.0 ± 0.18 (n=3). Figure 2A and the corresponding maximum intensity projection image (MIP) at 36 hours in Figure 2B . Quantitative data on the temporal uptake are depicted in Figure 2C&D .
High accumulation of 64 Cu-NOTA-FVIIai was seen in the liver, kidney and blood along with some tumor uptake at the 1 hour imaging time-point. 64 Cu-NOTA-FVIIai was excreted through both the kidneys and the hepatobiliary system (Figure 2A) , and the blood retention half-life was 1.6 hours when modeled as a one-phase decay. A significant increase in tumor to normal tissue contrast was observed throughout the imaging time-course ( Figure   2C&D ), and the tumors were clearly visible at 36 hours ( Figure 2B ).
However, no further improvement in tumor to muscle ratio was observed from 15 to 36 hours. Besides uptake in the liver, kidney and tumors, focal uptake was observed in the major joints.
by on October 21, 2017. For personal use only. jnm.snmjournals.org Downloaded from
The intra tumor uptake was rather heterogeneous. The average tumor uptake quantified by ROI analysis was 2.3 ± 0.2, 3.7 ± 0.3, 3.4 ± 0.3 and 2.4 ± 0.3 %ID/g at 1, 4, 15 and 36 hours after injection respectively ( Figure   2E ). In comparison, the maximum uptake within the tumors was significantly higher (6.6 ± 1.1, 9.5 ± 1.9, 9.4 ± 1.9 and 7.4 ± 1.4 %ID/g at 1, 4, 15 and 36 hours).
Biodistribution and competition
Conventional ex vivo biodistribution was performed at each of the imaging time-points ( Figure 3A) . The biodistribution results confirmed the data obtained by in vivo PET imaging and showed a relatively fast blood clearance and high retention in the liver, kidney and tumor. An increase in tumor-toblood, tumor-to-muscle and tumor-to-pancreas ratios was observed throughout the time-course of the biodistribution ( Figure 3B ). The ratios observed at 36 hours compared to 15 hours were all significantly higher (P ≤ 0.05). A competition experiment with unlabeled FVIIai was performed in a separate group of mice. Injection of unlabeled FVIIai prior to 64 Cu-NOTAFVIIai injection significantly reduced the tumor uptake (P ≤ 0.001), while the uptake in the other organs was unchanged, indicating a specific uptake of 64 Cu-NOTA-FVIIai in the tumors ( Figure 3C ).
Based on the longitudinal PET and biodistribution data it was decided to further evaluate 64 Cu-NOTA-FVIIai for PET imaging 15 hours after injection in a panel of pancreatic adenocarcinoma mouse models. In the current study we report a mean tumor uptake of 3.7 ± 0.3 %ID/g 4 hours after injection, which was significantly higher compared to the tumor uptake of 18 F-FVIIai at 4 hours (2.5 ± 0.3 %ID/g, P < 0.05) (19) . This could be attributed to the fact that the tumors in the current study were larger in comparison to the PET Imaging of TF has previously been investigated using a 64 Cu-labeled TF antibody and its Fab fragment (28, 29) . A superior tumor uptake of 16.5 ± 2.6 %ID/g 48 hours after injection of the 64 Cu-labeled full-length antibody was reported (28) . Despite the impressive tumor uptake, the tumor-tomuscle ratio was similar to what we report due to the long circulation of fulllength antibodies. The tumor uptake reported for the antibody Fab fragment was slightly higher, while the tumor-to-muscle ratio was about 50% lower than our results (29) .
Specific imaging of TF in a panel of subcutaneous pancreatic tumors
High uptake was seen in the liver and kidneys throughout the imaging time-course. This is similar to other reports and was most likely due to both clearance of intact 64 Cu-NOTA-FVIIai, instability of the chelation complex and accumulation of radiometabolites (30, 31) . As noted in the above-mentioned publication on a The cross reactivity between human FVIIai and murine TF is rather low (19, 32, 33) . This implies that the current study does not necessarily give a good estimate of the background uptake of mSv (male) and 10.9 mSv (female) which is about twice to that of FDG (35) but not considered prohibitive for the further development of 64 Cu-NOTAFVIIai as an imaging agent.
Conclusion
Non-invasive specific imaging of tumor TF expression was achieved using 
